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Medico-economic evaluation of infliximab in rheumatoid
arthritis—prospective French study of a cohort of 635 patients
monitored for two years
Jacques Sany1,*, Jean-David Cohen1,*, Christophe Combescure2,3, Marie-Ce´cile Bozonnat4,
Franc¸oise Roch-Bras1, Georges Lafon5 and Jean-Pierre Daure`s4
Objectives. To perform, in real conditions of prescription, the medico-economic evaluation of infliximab in severe RA.
Methods. A cost–effectiveness analysis of the annual costs was done with a comparison between the previous and the following year under
infliximab. The effectiveness, determined from the HAQ, was expressed in clinically significant units and in quality-adjusted life years
(QALYs). The incremental net benefit (INB), defined as willingness to pay (), was used to express the results.
Results. A cohort of 635 patients was formed. Before the use of infliximab, after 1 and 2 years, the mean annual cost per patient for the care
of RA was E9832, 27 723 and 46 704, respectively. Among the direct costs, infliximab accounts for E21 182 for the first year. The distribution
of the different costs was similar after 2 years. By using the INB, the difference before and after 1 year under infliximab is significant, on
average by 1.86 (S.E.M.¼ 0.76) when the effectiveness is expressed in clinically significant units. For severe HAQ,  is E9841 (18 593 for all
HAQ). When it is expressed in QALYs, also for severe HAQ, >E100 000. This can be explained by a short follow-up although severe
complication of RA appears later.
Conclusion. An evaluation of the more long-term costs is required in order to determine whether there are any full economic benefits
with this treatment.
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Introduction
The prevalence of RA in France, the most common chronic
inflammatory rheumatism, is between 0.31 and 0.40% of the
population, that is 130 000–150 000 individuals (95 000–210 000)
and its incidence 20/100 000 [1,2]. About 30% or 39 000–45 000
patients suffer from the refractory forms to MTX. RA being the
cause of major disability and alteration in quality of life has a high
social and economic cost. After 10 years of evolution, almost half
of the patients present a functional disability putting an end to
all professional life [1,2]. The costs induced are difficult to measure
since the clinical trials are generally too short to assess the
economic impact of treatment. Infliximab, a TNF- antagonist,
therapeutic class that revolutionized the care of RA [3,4], obtained
the marketing approval in Europe in 2000 for the treatment of
severe RA. The high price raises the question of its financing by
the public sector. In 2001, the French Health Department
included infliximab in a programme for the support of expensive
diagnostic and therapeutic innovations, which financed the treat-
ment of 2000 patients with public funds. The French Society of
Rheumatology was asked by it to co-ordinate the distribution of
this exceptional funding between the rheumatology departments
of university and general hospital centres according to their
active file of patients with RA and to establish a study for the
medico-economic evaluation of infliximab (EMER). The second-
ary goals of the study were to determine over 2 years, in clinical
practice, the efficacy and tolerance of infliximab, conditions of
its use and quality of life of the patients.
Patients and methods
Patients
The EMER study is an observational, prospective and multi-
centric study having involved 74 rheumatology departments in
university and general hospital centres. Of all the patients treated
with infliximab (initially 3mg/kg), we included one out of two
patients in the study. A cohort of 635 patients was thereby
formed and monitored for a period of 2 years after inclusion.
The subject’s written consent was obtained and the whole study
was approved by the Regional Ethics Committee for Medical
Research (Ethical Committee of Montpellier).
Efficacy criteria
We evaluated pain using visual analogue scale (VAS), global VAS
according to the doctor and the patient, disease activity score
(DAS) 28 [tendency test carried out on patients with a DAS28
rating at each evaluation (P< 0.0001)], functional capacity
with HAQ, quality of life using the Short Form 36 (SF-36),
ESR and CRP.
Medico-economic data
The analysis was carried out from the health insurance coverage
point of view, that is, the institutional payer. The economic
valorization was based on the direct (medical and non-medical)
and indirect costs related to the treatment of RA. The intangible
costs are not valorized as such but through their impact on the
quality of life. The direct medical costs include hospitalization
(administration of treatment and surgery), medical and technical
procedures (consultations, physiotherapy, lab tests and X-rays),
drug treatments and stays in convalescence homes or rehabilita-
tion centres. The direct non-medical costs are represented by the
transport (ambulance, non-emergency medical transport, private
car, etc.), home care and equipment of the home (installation of
railing, elevator, equipment of kitchen, etc.). The indirect costs are
related to a loss of productivity for the society (work stoppage
or disability of professionally active subjects) and include the
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patients still working at the time of inclusion. All consumption of
resources was noted by the patients (self-questionnaire). In order
to compare the costs before and under infliximab, the patient was
his own control and reported his consumption during the year
prior to inclusion. The monetary valorization was based on
the prevailing rates at the time of the analysis (2003; Table 1).
Statistical methodology
The characteristics of the patients were described by the median
(interquartile range) or by the mean S.D.; the HAQ and SF-36
scores were calculated according to the validated rules. An analy-
sis in repeated measurements was carried out using Friedman’s
test and contrast analysis. The costs were described (mean,
range) and compared between patients according to HAQ upon
inclusion (HAQ41, 1<HAQ41.5 and HAQ> 1.5 groups) by
using a Kruskal–Wallis test.
The marginal mean cost per patient was estimated using the
method developed by Willan et al. [5] consisting of carrying out,
at each interval separating two consecutive visits, linear regression
models on the costs observed (validity of the regression models
were checked on the non-censored data; results not shown).
The marginal mean total cost was then estimated using the regres-
sion parameters. This method is adapted to our data since it
can be used to introduce co-variates and take censored data into
account. A cost–effectiveness analysis was then carried out. The
effectiveness, estimated from the HAQ, was expressed in several
ways:
 in clinically significant units with a variation of 0.25 points
in the HAQ [6] for threshold value: a reduction of 1 point of
HAQ represents a gain of four clinically significant units;
 in quality-adjusted life years (QALYs):
 Based on Barton’s regression model [7] (QALY¼
0.862–0.327*HAQ) where a reduction of 1 point in the
HAQ represents an increase of 0.327 QALY with 95% CI
0.29, 0.37 (a random effect was introduced in the change of
HAQ in QALY from the standard error of the regression
parameters of the Barton’s model).
 Based on the Birmingham Preliminary Model (BPM) where
a reduction of 1 point of HAQ corresponds to an improve-
ment of 0.20 QALY [8].
The incremental net benefit (INB) [9, 10] is an indicator equivalent
to the cost–effectiveness ratio but easier to use. It is defined for
a willingness to pay  by the formula INB()¼ E – C where
E is the difference in the mean of efficacy between the previous
and first year under infliximab, and C the difference in the mean
of cost. INB()> 0 means that, for the willingness to pay , the
cost–effectiveness ratio is perhaps acceptable by the society and
will be so if the 95% CI is positive and lower than the acceptable
threshold  (E45 000 in France). The main analysis was performed
using the definition of a clinically significant unit by Krishnan
et al. [6] and the conversion of HAQ in QALYs using the
Barton et al. [7] and the BPM [8] models.
Results
Between November 2001 and April 2003, 635 patients (76%
women) were included. Of the 74 participating centres, 21 (28%)
recruited at least 10 patients. The leading five centres recruited
27% (169 patients) of the inclusions (Montpellier recruited
45 patients, Grenoble 35, Rouen 32, Nantes 29 and Strasbourg
28). The mean age at the first symptoms, diagnosis and inclusion
(prescription of infliximab) were 40.9 13.0, 42.3 13.0 and
53.4 11.8 years, respectively. Seropositivity for the RF, tenosy-
novitis and rheumatoid nodules were noted in 86, 36 and 22% of
the patients, respectively (Table 2). The median DAS28 is
5.82 (5.15–6.56) and 87% of the patients presented radiographic
erosions, attesting to active and severe RA. Over 90% of the
patients were treated with at least one NSAID and 98.7% with
MTX.
Upon inclusion, the median VAS for pain was at 59 (43–70)
and quickly decreased as of the second week of treatment, to
40 (25–53). After 1 year and, globally, 2 years of treatment, the
median VAS decreased by 49% (P< 0.0001) and 58%, respec-
tively. The median global VAS according to the patient decreases
by 59% and globally by 62% (P< 0.0001), respectively. The
scores provided by the doctors followed the same evolution
(56 and 63% reduction, respectively). The initial median DAS28
(Fig. 1A) of the completers was 5.65 and decreased to 4.2 after
2 weeks. After the first and second years, the reduction continued
with a score of 3.46 and 3.36, respectively. The initial median
HAQ (Fig. 1B) of the completers was 1.63. After the first and
second years, the reduction continued with a score of 1. Upon
inclusion, all of the items comprising the SF-36 score were altered
and improved perceptibly as of the third perfusion and stabilized
during the 2-year period.
The treatment was prematurely interrupted by 391 patients.
Causes were inefficacy (17% of all patients treated), serious (10%)
or non-serious adverse effect (6%) and patient’s wish (7%).
TABLE 1. Fees
Type of cost Nature of the cost Reference fees Fees at the time of the study
Direct medical costs Hospitalization National cost scale most adapted to the type of
intervention
National ISA point: E2.11
Medico-technical procedures General nomenclature fees for professional
procedures
CS (consultation): E23
AMC (physiotherapy and ergotherapy): E1.98
Rating from the key letter þ coefficient of the
procedures performed
B (lab tests): E0.27
Z (X-rays): E1.33
Drug treatments 2003 prices for infliximab and drugs reserved
for hospital use
Infliximab 2003a: E711 for one 100 mg bottle
Public price for drugs not reserved to hospital
Rest home E127.33 per day
Rehabilitation centre E203.80 per day
Direct non-medical costs Medicalized transport National health rates (Languedoc-Roussillon Private car: E0.26/km
region) Ambulance: E52 (trip <5 km) or E2/cm (trip >5 km)
Non-emergency medical transport: E0.78/km
N.B.: 100% reimbursement of expenses in disease with
long-term disability
Equipment and home care According to the information provided by the patient
Indirect costs Work stoppages According to the socioprofessional category Employees and labourers: E63.30 per day
Disabilities INSEE scale for average annual net salaries of Intermediate professions: E74.90 per day
civil servants in 2000 Managers: E110.30 per day
aPrice at the time of the study.
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At the beginning, almost all of the patients responded with only
16 (3%) interruptions for inefficacy. After the first four
perfusions, the greatest number of drop-outs due to inefficacy
was observed in 50 (9%) patients; during the past 50 weeks, the
interruption was possible at all times, in 43 (11%) patients.
Of the 635 patients receiving at least one perfusion, 2002
adverse effects were reported in 522 (82%) of them. The main
adverse effects consisted of infection (51% of the adverse effects)
of bacterial (68% of the infections including one tuberculosis
and three septicaemias), viral (50%), herpes (7%), fungal (7%)
and parasitic (0.6%, one strongyliasis and one taenia) origin.
No cases of lymphoma were detected. Five deaths were noted of
which two were attributed to infliximab (one miliary tuberculosis
and one septicaemia).
Among the 403 and 244 patients treated, respectively, for 1 year
and during the entire study, 18% (73) and 21% (52), respectively,
presented at least one reaction to the perfusion. The mean number
of reactions was 2.6 and 4.6, respectively, during the first
and second years. The highest frequency (6%) was observed as
of the first perfusion and tended to decrease, very slightly over
time. During the first and second years of the study, respectively,
188 (4%) and 238 (3.7%) reactions were noted for 4676 and
6448 perfusions. This reaction was therefore independent of the
duration of the treatment.
The initial mean dose of infliximab administered was
3.16mg/kg, then increased, after first (374 patients) and second
years (244 patients), to 3.44mg/kg (þ9%) and 3.56mg/kg
(þ13% with respect to the initial dose), respectively. The 403
and 244 patients treated, respectively, during the first and
second years received an average of 8.9 and 14.7 perfusions,
respectively.
Medico-economic results
Among the 403 (63.5%) and 244 (38.4%) patients still monitored
over the first and second years, 355 (88%) and 163 (67%), respec-
tively, completed all of the medico-economic questionnaires.
The average cumulative annual cost was E27 665 per patient
after the first year, of which 88.4, 10.4 and 1.2% was due to the
direct medical (essentially hospitalization, infliximab), indirect
(loss of production) and direct non-medical (transport) costs,
respectively. Infliximab accounted for E21 232 (drug, preliminary
lab tests and hospitalization for perfusion) in the first year or
76.7% of the total costs. After 2 years, the cumulative cost repre-
sented E47 295 per patient with a similar distribution of the
different costs. Before the use of infliximab, the mean annual
cost for the treatment of RA was E9831. During the first year,
excluding the cost of infliximab, it decreased to E6433 (–34.6%,
P< 0.01) due to the reduction in direct medical (22.5%), indirect
(32.1%) and direct non-medical (77.3%) costs. The detailed
examination of the direct medical costs (excluding infliximab)
revealed a decrease in all of the components (P< 0.01) (hospitali-
zation, drugs, surgery, etc.) except for the physiotherapy (multi-
plied by over five during the first year). The cost was analysed
according to the HAQ (HAQ41, 1<HAQ41.5,
1.5<HAQ43) upon inclusion (Table 3). After the first year, a
significant difference was noted between the levels of HAQ for the
total costs (P¼ 0.03) as before the administration of infliximab
(P< 0.01). The costs remained higher in patients with a major
functional disability. After 2 years, the difference (including, in
this case, the indirect costs) was not significant (P¼ 0.07), but
the tendency was the same. The difference concerned the direct
non-medical and indirect medical costs. The direct medical costs
were significantly different the previous year according to the
HAQ, but not after first and second years (Table 3).
When the effectiveness was expressed in clinically significant
units (1 U equivalent to 0.25 HAQ points), the difference between
the previous and first year under infliximab was significant, mean
of 1.86 (95% CI 1.72, 2.00). For the HAQ 41, 1<HAQ41.5
and HAQ> 1.5 groups at inclusion, the differences were 0.80
(95% CI 0.46, 1.14), 1.69 (95% CI 1.25, 2.12) and 2.24 (95% CI
1.85, 2.63), respectively. In the total sample, the INB() was sig-
nificantly positive for > 18 593. According to the HAQ, it was
for > 41 821, 14 721 and 9841, respectively (Fig. 2).
When the effectiveness was expressed in QALYs, using
Barton’s model (with a random effect), the mean difference of
QALY was significant in whole sample (0.15; 95% CI 0.10,
0.20), in 1<HAQ41.5 and HAQ> 1.5 groups [0.14 (95% CI
0.06, 0.21) and 0.18 (95% CI 0.11, 0.25), respectively], but not
TABLE 2. Characteristics of the patients
Parameter n Value
Number of swollen joints, median (IQR) 630 9 (5–13)
Number of painful joints, median (IQR) 624 12 (7–17)
Morning stiffness, median (IQR), min 629 90 (45–120)
Pain VAS, median (IQR) 626 59 (44–70)
Global patient VAS, median (IQR) 622 65 (50–78)
Global doctor VAS, median (IQR) 598 60 (45–70)
DAS28, median (IQR) 604 5.82 (5.17–6.56)
ESR (mm/1st h), median (IQR) 618 28 (15–44)
CRP, median (IQR), mg/l 614 20 (8–39)
Haemoglobin, median (IQR), g/dl 626 12.4 (11.5–13.4)
Seropositivity for RF,% 551 473 (86)
Anti-filaggrin antibody, n (%) 501 187 (37)
Antinuclear antibody, n (%) 350 285 (50)
Tenosynovitis, n (%) 635 228 (36)
Rheumatoid nodules, n (%) 635 139 (22)
Radiographic erosions, n (%) 589 514 (87)
Narrowing joint, n (%) 589 512 (87)
Treatments already prescribed, n (%)
NSAID, n (%) 625 584 (93.4)
Corticosteroid, n (%) 622 586 (94.2)
Hydroxychloroquine, n (%) 618 382 (61.8)
Gold salts, n (%) 620 356 (57.4)
Penicillamine, n (%) 602 141 (23.4)
Sulfasalazine, n (%) 611 316 (51.7)
MTX, n (%) 629 621 (98.7)
Azathioprine, n (%) 591 49 (8.3)
Cyclosporin, n (%) 595 78 (13.1)
Leflunomide, n (%) 614 337 (54.8)
IQR: interquartile range.
FIG. 1. Evolution of (A) the median DAS28 score and (B) the HAQ score.
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in the group HAQ< 1 (0.07; 95% CI 0.00, 0.13). The INB() was,
in the total sample, significantly positive for > 249 663. In the
HAQ41, 1<HAQ41.5 and HAQ> 1.5 groups, it was signifi-
cantly positive for > 1 107 472, 215 343 and 135 812, respectively.
Using the BPM model, it was significantly positive for > 371 714
in the total sample and, in the HAQ41, 1<HAQ41.5 and
HAQ>1.5 groups, for > 836 379, 294 314 and 196 653,
respectively.
Discussion
The EMER study has confirmed the efficacy of infliximab in real
life. A Swedish study [11] comparing cohorts treated by infliximab
and etanercept, demonstrated an interruption in treatment after
2 years for half and one-quarter of the patients, respectively.
An English study [12] based on registers demonstrated, after
6 months, the similar therapeutic maintenance under infliximab
and etanercept for 79 and 80% of the patients, respectively.
A Belgian study on 511 RA patients [13], demonstrated after
4 years, a maintenance under infliximab of 61.6%. In a Dutch study
on 120 RA patients [14], 66% were still under infliximab after
1 year. In France, a therapeutic maintenance of 70% after 2 years
was reported in 50 patients [15]. In our study, out of 635 patients,
a therapeutic maintenance of 64% was noted after 1 year.
A retrospective American study [16] based on registers demon-
strated, in 89 RA patients treated by infliximab, an average
increase in the initial dose (3mg/kg) of 33% after 24 months.
Another study [17] in 141 patients demonstrated a 37.4% increase
in dosage. After 2 years, our study demonstrated the same
tendency with over one-quarter of the patients treated with
>3mg/kg. The efficacy in our study was similar to that of the
ATTRACT study [3], in particular as regards the HAQ, as well
as the profile of serious adverse effects and reactions to the
perfusions.
As regards the economic data, a retrospective French
study, comparing etanercept and infliximab in 58 patients [18],
TABLE 3. Cost of treatment in euros by level of HAQ score
Previous year 1 year 2 years
HAQ groups Mean cost, E Range Pa Mean cost, E Range Pa Mean cost, E Range Pa
Direct medical costs All HAQ 4175 [0–78 011] 24 453 [17 266–54 885] 41 375 [28 647–87 181]
HAQ<1 3093 [91–21 508] 23 593 [17 917–35 068] 40 453 [28 647–79 946]
1<HAQ<1.5 3689 [0–25 487] 0.009 23 502 [17 266–40 023] 0.12 39 907 [29 307–61 430] 0.33
HAQ>1.5 4628 [80–78 011] 25 125 [17 346–54 885] 42 403 [29 875–87 181]
Direct non-medical costs All HAQ 1418 [0–21 342] 322 [0–3519] 626 [0–8782]
HAQ<1 554 [0–3219] 181 [0–1591] 368 [0–2434]
1<HAQ<1.5 893 [0–4776] <0.001 274 [0–2531] 0 497 [0–3912] 0.01
HAQ>1.5 1834 [0–21 342] 383 [0–3519] 775 [0–8782]
Indirect costs All HAQ 4239 [0–40 260] 2875 [0–44 672] 5294 [0–36 582]
HAQ<1 2986 [0–23 119] 2245 [0–25 653] 3512 [0–34 619]
1<HAQ<1.5 4190 [0–23 119] 0.002 2800 [0–23 424] 0.04 5285 [0–24 062] 0.01
HAQ>1.5 4554 [0–40 260] 3083 [0–44 672] 5893 [0–36 582]
Total costs All HAQ 9831 [138–87 417] 27 650 [17 957–76 237] 47 295 [29 875–98 480]
HAQ<1 6633 [202–28 485] 26 020 [17 986–57 007] 44 333 [29 922–85 532]
1<HAQ<1.5 8773 [138–31 883] <0.001 26 575 [18 105–54 361] 0.03 45 689 [30 753–65 318] 0.07
HAQ>1.5 11 016 [169–87 417] 28 591 [17 957–76 237] 49 070 [29 875–98 480]
aComparisons using a Kruskal–Wallis test.
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FIG. 2. INB (with 95% CI). The effectiveness was expressed in clinically significant units.
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demonstrated that the mean cost is similar, E19 500 per year,
70% (for infliximab) was attributed to the cost of the drug. A
retrospective American study in patients aged >65 years [19] eval-
uated the annual cost under infliximab at $35 000, 50% was due
to the cost of the drug. Our study found similar results with an
average cost, in the first year, of E21 232 for infliximab, the total
medical care of the patient amounting to E27 665.
Cost–effectiveness studies published on infliximab in
RA patients were retrospective, comparative with a reference
cohort and did not always include the indirect costs. Two analyses
were carried out in parallel [20], in Great Britain and Sweden. The
difference in clinical efficacy between infliximab and MTX in the
ATTRACT study was used as a reference to which the epidemio-
logical data and consumption of resources and the official rates
for each country were applied. The ERAS study grouping
1473 RA patients for Great Britain and a cohort of 183 patients
for Sweden, monitored for an average of 7.8 and 11.3 years,
respectively, were considered. The costs and consequences of
the progression of the RA were estimated with Markov’s model.
The difference in the results [20] between the two countries was
most likely due to the higher indirect costs in Sweden in case
of a progression of the disability. Thereby, when the RA was
controlled, the price to pay for the monitoring was lower than
that in Great Britain. An American study [21] also extrapolated
the clinical results from the ATTRACT study on the ARAMIS
cohort (4258 patients), representing a total of 17 085 patients/
years. The cost of treatment was based on the fees relating to a
perfusion (3mg/kg) repeated 8 and 15 times, respectively, in the
first and second year. The indirect costs were determined in the
subgroup of patients employed upon inclusion. The analysis
demonstrated that the association of infliximab–MTX (vs MTX
alone) for first or second year increased the life expectancy
expressed in QALYs. Modelization of the cost–efficacy ratio,
carried out in Great Britain in the National Institute for Health
and Clinical Excellence study [22], estimated the cost at £38 000/
QALY for the use of infliximab in RA. In our study, it was only
possible to enter the costs the previous year and for the 2 years of
treatment. In these conditions, the annual cost of the medical
treatment (infliximab–MTX association) represented the main
cost. The similarity of the results, whatever the method used to
express the effectiveness from the HAQ, provided us with the
strength of the conclusion. The results in QALY demonstrated
that for patients with an HAQ41.5 and more specifically41,
the resources devoted to gain 1 U of effectiveness were much
higher than for the other patients (HAQ> 1.5). In other words,
the more severe the RA, the more cost-effective was infliximab.
For these severe patients, the INB was significantly in favour of
infliximab for values of willingness to pay>E135812 andE193653
according to the model, which was not acceptable in our society. A
short follow-up can be a problem for cost-effective study in chronic
disease.
Our study was of interest since it was carried out in real life,
in a prospective manner, on a large number of patients without
comparison with another cohort. The economic analysis did
not demonstrate the cost–effectiveness using INB because the
follow-up is very short. Part of the cost of infliximab was made
up for by a reduction in hospitalizations as of the first year.
The evaluation of the long-term costs was required in order to
determine the full economic benefits of this treatment. In 2001,
infliximab was the only anti-TNF- agent available in France.
As several biotherapy agents are now available to treat RA, it is
probably inadequate to follow a cohort of patients for a long time
on the same treatment. Medico-economic studies should be
carried out taking the different therapeutic strategies into account
(substitution, association) in clinical practice within a single
cohort. Then the study period on a specific drug should remain
short. This issue, when results are compared with a Markov
model, has a conservative approach as a consequence (under
evaluation of drug efficiency).
Rheumatology key messages
 The costs induced by biotherapies are important but difficult to
measure.
 Our medico-economic analysis of infliximab in RA demonstrated
gains in units of efficacy for patients but not in QALY on two years
of follow-up.
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Centre Hospitalier de Gonesse, Gonesse; Dr Golberg, Centre
Me´dico-Chirurgical de la Porte de Pantin, Paris; Prof. Goupille,
CHU—Hoˆpital Trousseau, Tours; Dr Guyot, Centre Hospitalier
Victor Provo, Roubaix; Dr Hacene, CHU Amiens Nord, Amiens;
Dr Hilliquin, Hoˆpital Gilles de Corbeil, Corbeil Essonnes;
Dr Hoang, Centre Hospitalier de Vannes, Vannes; Dr
Houvenagel, Centre Hospitalier Saint Philibert, Lomme; Prof.
Jean Baptiste, CHU—Fort de France, Fort De France; Prof.
Lafforgue, Hoˆpital de la Conception, Marseille; Dr Lamotte,
Hoˆpital Le´opold Bellan, Paris; Dr Larbre, CHU—Hoˆpital
Pierre Benite, Lyon; Dr Le Quere, CHU—Hoˆpital de Bois-
Guillaume, Rouen; Prof. Le Parc, CHU—Hoˆpital Ambroise
Pare´, Boulogne-Billancourt; Dr Lequen, Centre Hospitalier,
Pau; Dr Lespessailles, Centre Hospitalier Re´gional, Orleans; Dr
Lifermann, CHG de Dax, Dax; Prof. Maillefert, CHU Hoˆpital
ge´ne´ral, Dijon; Dr Marce, Centre Hospitalier de la Coˆte Basque,
Bayonne; Prof. Marcelli, CHU Caen, Caen; Dr Martin, Centre
Hospitalier de Saint Brieuc, Saint Brieuc; Prof. Meyer, Hoˆpital
Bichat, Paris; Dr Mimoune,Hoˆpital Gilles de Corbeil, Corbeil
Essonnes; Prof. Miossec, CHU—Hoˆpital Edouard Herriot,
Lyon; Dr Mizony, Centre Hospitalier Henri Mondor, Aurillac;
Dr Monvoisin, Centre Hospitalier de Troyes, Troyes; Dr
Morlock, Centre Hospitalier Andre´ Gayraud, Carcassonne;
Dr Mouries, Hoˆpital Rhumatologique, Uriage; Prof. Orcel,
CHU—Hoˆpital Lariboisie`re, Paris; Dr Pallot-Prades, CHU—
Hoˆpital Bellevue, Saint-Etienne; Dr Pavy, CHU—Hoˆpital
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Cochin, Paris; Prof. Perdriger, CHU Rennes, Rennes; Dr
Pertuiset, Centre Hospitalier Rene´ Dubos, Pontoise; Prof.
Pourel, CHU—Hoˆpital Brabois, Vandoeuvre Les Nancy; Dr
Rajzbaum, Hoˆpital Saint Joseph, Paris; Dr Ramon, Centre
Hospitalier d’Avallon, Avallon; Prof. Ristori, Hoˆpital G.
Montpied, Clermont-Ferrand; Prof. Roux, CHU—Hoˆpital
Cochin, Paris; Dr Roux, Hoˆpital Saint Joseph, Paris; Dr Saint
Marcoux, Hoˆpital Robert Ballanger, Aulnay Sous Bois; Prof.
Saraux, CHU—Hoˆpital La Cavale Blanche, Brest; Dr Siame,
Polyclinique de Riaumont, Lievin; Prof. Sibilia, CHU—Hoˆpital
de Hautepierre, Strasbourg; Dr Sidot, Centre Hospitalier de
Montceau les Mines, Saint Vallier; Dr Simon, Hoˆpital National
de Saint Maurice, Saint Maurice; Dr Solau-Gervais, CHRU—
Hoˆpital R. Salengro, Lille; Prof. Tebib, Hoˆpital Pierre Benite,
Lyon; Dr Thomas, CHU—Hoˆpital Lapeyronie, Montpellier; Dr
Thorel, Centre Hospitalier de Bretagne Sud, Lorient; Dr Valenza,
CHG de Draguignan, Draguignan; Prof. Wendling, CHU Jean
Minjoz; Besancon; Dr Zabraniecki, CHU—Hoˆpital Purpan,
Toulouse; Dr Zarnitzky, Groupe Hospitalier du Havre, Le Havre.
Funding: In 2001, the French Health Department (Direction de
l’Hospitalisation et de l’Offre de Soins: DHOS) included inflixi-
mab in a programme for the support of expensive diagnosis and
therapy. Socie´te´ Franc¸aise de Rhumatologie (SFR) was asked by
DHOS to co-ordinate the distribution of funding between the
rheumatology departments of University Hospital Centres
(Centres Hospitalo-Universitaires: CHU) and General Hospital
Centres (Centres Hospitaliers Ge´ne´raux: CHG) according to
their active file of patients with RA and establish a study for
the EMER. The statistical analysis was funded by DHOS.
The contract research organization was funded by Schering-
Plough Laboratories.
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